Headed to San Francisco? Here’s how you can customize your experience at #JPM24 with Endpoints News
That said, there’s also a fundamental belief that the science behind new drug development and the goals biotech execs set for themselves remain more ambitious than at any time I’ve observed the industry over the past 21 years. It’s a time to reaffirm the fundamentals and show investors the data.
Slowly and gradually, the industry can start returning to a more normal mix of M&A, follow-ons and IPOs, much though the FTC seems determined to throw a monkey wrench into the machine.
All of the news, delivered with full-text to your inbox. For professionals discovering, developing, and marketing biopharmaceutical drugs.
Their timing on scuttling the Sanofi/Maze deal was impeccably awful. Could there be a worse moment to raise a question mark over biotech’s role in developing next-gen drugs that almost always end up in the hands of the Big Pharma brethren that steer the big marketing groups?
The implications will be debated for months to come as 2024 unfolds. And Endpoints News will have a role in shaping the discussion in San Francisco early in January.
I’m inviting you to be a part of that.
Every year, we up the ante quite a bit at JP Morgan. Back at the beginning for Endpoints, Arsalan Arif and I were happy to pull off a breakfast. This year, with a big boost from Drew Armstrong and a much-expanded editorial team, we have 18 separate events spread out over two days at the Marriott Marquis.
Now, we’d love it if you planned to make the Marriott Marquis your headquarters for the first two days of JPMorgan. We’ve got lots of space, including plenty of room for you to work out of. At the same time, there’s lots going on (here’s a link to the full agenda), and you’ll likely want to pick and choose your events and times. So, here are three links designed for you to either go all in or customize your schedule and reduce your costs.
The discussions we have planned center on the future of drug development, the biggest issues confronting biotech in 2024 and roundtables that get to the gist of leading a biotech during a long, cold spell on Wall Street — and in Washington DC.
Drew recently penned a detailed description of what we have planned. I’m going to let him take it away:
I’ve spent the last month+ working with our team Endpoints News to lock in our #JPM2024 agenda, and whoooooa boy is it gonna be good. Here are some highlights:
🔬 Pfizer’s Mikael Dolsten and Merck’s Eliav Barr will talk about the future of R&D with John Carroll and me.
💊 Walgreens’ new CEO Tim Wentworth + Lydia Ramsey Pflanzer will discuss where the pharmacy company is going next.
🏅 Nobel Prize winner Carolyn Bertozzi will sit down with Nicole DeFeudis + John Carroll to talk about her research, career and much more.
🤝 A one-on-one the banker behind pretty much every pharma deal of the year, Centerview Partners’ E. Eric Tokat.
👀 Conversations with Gilead Sciences CMO Merdad Parsey, Vir Biotechnology CEO Marianne De Backer, AstraZeneca CFO Aradhana Sarin, Catalent Pharma Solutions CEO Alessandro Maselli, Flagship founder Noubar Afeyan.
🎯 The activists are here! Andrew Dunn will sit down with Elliott Investment Management’s Marc Steinberg.
If you have any questions, let us know.